Valuation: Lipocine Inc.

Market Cap 11.87M 10.63M 9.78M 8.86M 16.56M 1.13B 16.87M 117M 46.82M 593M 44.55M 43.61M 1.87B P/E 2026 *
-0.93x
P/E 2027 * -1.07x
Enterprise Value 11.87M 10.63M 9.78M 8.86M 16.56M 1.13B 16.87M 117M 46.82M 593M 44.55M 43.61M 1.87B EV / Sales 2026 *
18.8x
EV / Sales 2027 * 15.9x
Free-Float
95.03%
Yield 2026 *
-
Yield 2027 * -
1 day-5.26%
1 month-30.43%
3 months-32.08%
6 months-38.20%
Current year-82.07%
1 week 1.42
Extreme 1.42
1.56
1 month 1.4
Extreme 1.4
3.15
Current year 1.4
Extreme 1.4
12.37
1 year 1.4
Extreme 1.4
12.37
3 years 1.4
Extreme 1.4
12.37
5 years 1.4
Extreme 1.4
32.13
10 years 1.4
Extreme 1.4
90.61
Manager TitleAgeSince
Chief Executive Officer 69 01/01/1997
Chief Tech/Sci/R&D Officer 56 01/12/2022
Chief Tech/Sci/R&D Officer 68 -
Director TitleAgeSince
Chairman 69 08/01/2014
Director/Board Member 58 01/01/2003
Chairman 73 20/04/2026
Date Insider Type Main position Quantity % Market Cap. Importance
30/9/26 Buy

Director

15,970 0.1937%
28/9/26 Buy

Director

12,561 0.1524%
3/8/26 Free

Director

2,000 0.0243%
Change 5-day change 1-year change 3-year change Capi.($)
-5.26%-.--%-45.86%-43.75% 11.87M
-0.62%-1.87%+42.87%+67.17% 63.77B
+0.35%+3.20%+14.40%+73.89% 56.37B
+0.53%+1.96%+16.24%+102.20% 54.62B
-2.81%-4.31%+23.50%+48.51% 44.06B
-0.33%-1.93%+19.28%+104.26% 42.11B
+0.55%+2.31%+225.14%+840.10% 41B
+3.27%+47.96%+112.84%+91.02% 34.92B
+1.22%-1.44%+14.57%+47.05% 32.82B
+0.89%+20.55%-40.62%+350.50% 24.7B
Average -0.22%+6.79%+38.23%+168.09% 39.44B
Weighted average by Cap. +0.18%+5.44%+47.99%+173.40%

Financials

2026 *2027 *
Net sales 631K 565K 520K 471K 881K 59.94M 897K 6.2M 2.49M 31.53M 2.37M 2.32M 99.43M 745K 667K 614K 556K 1.04M 70.74M 1.06M 7.32M 2.94M 37.21M 2.8M 2.74M 117M
Net income -12.64M -11.32M -10.41M -9.44M -17.64M -1.2B -17.97M -124M -49.86M -631M -47.45M -46.44M -1.99B -16.22M -14.52M -13.36M -12.11M -22.63M -1.54B -23.05M -159M -63.96M -810M -60.86M -59.57M -2.55B
Net Debt - -
Projected Income Statement - Annual - Lipocine Inc.
Logo Lipocine Inc.
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Employees
14
Date Price Change Volume
30/10/26 USD 1.440 -5.26% 112,048
29/10/26 USD 1.520 +0.66% 139,127
28/10/26 USD 1.510 +3.42% 194,658
27/10/26 USD 1.460 +0.69% 129,469
26/10/26 USD 1.450 +0.69% 108,937
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Lipocine Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.440USD
Average target price
5.000USD
Spread / Average Target
+247.22%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lipocine Inc.
  1. Stock Market
  2. Stocks
  3. LPCN Stock